Scientists in Germany have made significant breakthroughs with a new nasal vaccine against Covid-19. The vaccine has shown promising early results in hamster experiments, where it was able to completely eliminate the virus from the animals' upper airways after just two doses.
The vaccine uses a live but weakened form of the coronavirus, which is similar to how some other vaccines work. However, unlike traditional injectable vaccines, this nasal vaccine can be delivered directly into the nose and throat, where the virus first enters the body.
According to studies published in the journal Nature Microbiology, two doses of the vaccine were able to create a much stronger immune response than two doses of an mRNA-based vaccine or one that uses an adenovirus to ferry its instructions into cells. The researchers believe that this approach could be more effective at preventing infection and reducing the severity of Covid-19 symptoms.
The nasal vaccine works by mimicking the process of a natural infection, with the weakened virus being presented to the immune system in a way that allows it to build up immunity against future infections. This approach has been used before, dating back to the 1870s, but its revival is seen as promising given the ongoing need for effective Covid-19 vaccines.
The research team behind the vaccine, led by Dr. Emanuel Wyler, has partnered with a Swiss company called RocketVax to start phase I clinical trials in humans. The results of these trials are expected to be announced soon, although it's unclear how well the vaccine will perform in real-world settings.
Other nasal vaccines for Covid-19 are also in various stages of development and testing, including some that use harmless adenoviruses to deliver their instructions into cells. While some have shown promising results, others have struggled to raise sufficient funding or overcome technical challenges.
Despite these developments, researchers remain cautious about the prospects for this new approach. Respiratory infections can be notoriously difficult to target with inhaled vaccines, and there are concerns that even a weakened form of the virus could pose risks to certain populations, such as those with compromised immune systems.
However, Wyler notes that while it's true that "even a strongly attenuated virus is still a real virus," he believes that this one has been effectively hobbled through genetic modification. The key will be to carefully test and refine this vaccine in humans before it's widely available.
For now, the emergence of this new nasal vaccine represents a promising development in the ongoing quest for effective Covid-19 treatments. With its potential to prevent infection and reduce symptoms, it could help bring an end to the pandemic β or at least make life easier for those already living with the virus.
The vaccine uses a live but weakened form of the coronavirus, which is similar to how some other vaccines work. However, unlike traditional injectable vaccines, this nasal vaccine can be delivered directly into the nose and throat, where the virus first enters the body.
According to studies published in the journal Nature Microbiology, two doses of the vaccine were able to create a much stronger immune response than two doses of an mRNA-based vaccine or one that uses an adenovirus to ferry its instructions into cells. The researchers believe that this approach could be more effective at preventing infection and reducing the severity of Covid-19 symptoms.
The nasal vaccine works by mimicking the process of a natural infection, with the weakened virus being presented to the immune system in a way that allows it to build up immunity against future infections. This approach has been used before, dating back to the 1870s, but its revival is seen as promising given the ongoing need for effective Covid-19 vaccines.
The research team behind the vaccine, led by Dr. Emanuel Wyler, has partnered with a Swiss company called RocketVax to start phase I clinical trials in humans. The results of these trials are expected to be announced soon, although it's unclear how well the vaccine will perform in real-world settings.
Other nasal vaccines for Covid-19 are also in various stages of development and testing, including some that use harmless adenoviruses to deliver their instructions into cells. While some have shown promising results, others have struggled to raise sufficient funding or overcome technical challenges.
Despite these developments, researchers remain cautious about the prospects for this new approach. Respiratory infections can be notoriously difficult to target with inhaled vaccines, and there are concerns that even a weakened form of the virus could pose risks to certain populations, such as those with compromised immune systems.
However, Wyler notes that while it's true that "even a strongly attenuated virus is still a real virus," he believes that this one has been effectively hobbled through genetic modification. The key will be to carefully test and refine this vaccine in humans before it's widely available.
For now, the emergence of this new nasal vaccine represents a promising development in the ongoing quest for effective Covid-19 treatments. With its potential to prevent infection and reduce symptoms, it could help bring an end to the pandemic β or at least make life easier for those already living with the virus.